Vaxcyte (PCVX) COO logs planned stock sales and RSU tax withholding

Rhea-AI Filing Summary

Vaxcyte, Inc. chief operating officer Jim Wassil reported recent stock transactions. On March 9, 2026, 975 shares of common stock were surrendered to the company to cover tax withholding obligations upon RSU vesting, which is an automatic, non-market disposition.

On March 10, 2026, he completed two open-market sales totaling 7,395 shares of common stock at weighted-average prices of $58.316 and $59.160. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly holds 166,818 shares of Vaxcyte common stock, indicating that he retains a substantial equity position.

Insider Trade Summary 10b5-1

Net Seller: 7,395 shares ($435,440)

Net Sell 3 txns

Insider Wassil Jim

Role CHIEF OPERATING OFFICER

Sold 7,395 shs ($435K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,427	$58.316	$142K
Sale	Common Stock	4,968	$59.16	$294K
Tax Withholding	Common Stock	975	$59.32	$58K

Holdings After Transaction: Common Stock — 171,786 shares (Direct)

Footnotes (1)

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.725 to $58.715. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wassil Jim

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F		975(1)	D	$59.32	174,213	D
Common Stock	03/10/2026		S(2)		2,427	D	$58.316(3)	171,786	D
Common Stock	03/10/2026		S(2)		4,968	D	$59.16(4)	166,818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.

2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.725 to $58.715. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The price reported is a weighted-average price. The shares were sold at prices ranging from $58.74 to $59.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Vaxcyte (PCVX) COO Jim Wassil report?

Vaxcyte COO Jim Wassil reported surrendering 975 shares for tax withholding on RSU vesting and selling 7,395 common shares in open-market transactions. The activity occurred on March 9–10, 2026, and was disclosed in a Form 4 filing.

Were the Vaxcyte (PCVX) insider stock sales part of a 10b5-1 plan?

Yes, the reported Vaxcyte stock sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. Such plans schedule trades in advance, making the timing more routine and less tied to short-term company developments.

How many Vaxcyte (PCVX) shares did the COO sell and at what prices?

The COO sold a total of 7,395 Vaxcyte common shares in two open-market transactions. The weighted-average sale prices were $58.316 and $59.160 per share, with detailed price breakdowns available upon request from the reporting person.

What was the purpose of the 975 Vaxcyte (PCVX) shares surrendered by the COO?

The 975 shares were surrendered to Vaxcyte to cover tax withholding obligations triggered by the vesting of restricted stock units. This is a tax-related disposition, not an open-market sale, and is common when equity awards vest.

How many Vaxcyte (PCVX) shares does the COO hold after these transactions?

Following the reported transactions, Jim Wassil directly owns 166,818 shares of Vaxcyte common stock. This post-transaction holding indicates he maintains a significant ongoing ownership stake in the company despite the recent sales and tax withholding surrender.

Does the Vaxcyte (PCVX) Form 4 show any remaining stock options or derivatives?

The Form 4’s derivative section is empty, indicating no derivative securities, such as stock options or warrants, are reported as remaining positions in this particular filing. Only non-derivative common stock transactions are disclosed here.